Mayo Clinic-ko ikertzaileekin lankidetzan egindako argitalpenak (35)

2021

  1. Authors reply to the letter to editor with regard to the article titled “Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping”

    Cytometry Part B - Clinical Cytometry

  2. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144

  3. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 142-155

  4. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 156-182

  5. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  6. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference

    Journal of Allergy and Clinical Immunology

  7. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 11, pp. 3918-3928

  8. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 132-138

  9. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

    HemaSphere, Vol. 5, Núm. 11, pp. E646